• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性慢性免疫性血小板减少症患者的长期临床结局:一项丹麦基于人群的队列研究。

Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study.

机构信息

Department of Clinical Epidemiology, Aarhus University Hospital, Sdr Skovvej 15, Aalborg, Denmark.

出版信息

Blood. 2011 Mar 31;117(13):3514-20. doi: 10.1182/blood-2010-10-312819. Epub 2011 Jan 24.

DOI:10.1182/blood-2010-10-312819
PMID:21263148
Abstract

Few data exist on the long-term prognosis of patients with chronic primary chronic immune thrombocytopenia (ITP). We examined the risk of infections, hemorrhage resulting in hospitalization, hematologic malignancies, and total and cause-specific mortality among patients with ITP compared with the general population. We used population-based medical databases to identify 407 patients with primary chronic ITP diagnosed during 1996 to 2007 and 4069 general population members individually matched on age, sex, and comorbidity level. We used Cox regression analysis to estimate rate ratios (RRs) adjusted for age (≤ 60 or > 60 years), sex, calendar year, and level of comorbidity. The adjusted 1-year RR of infection was 4.5 (95% confidence interval [CI], 3.3-6.1) for patients with chronic ITP compared with the general population cohort. The adjusted RR decreased to 1.8 (95% CI, 1.3-2.5) for the second to fifth year of follow-up. The adjusted 5-year RR was 3.2 (95% CI, 1.2-9.0) for hospitalized intracranial hemorrhage, 4.4 (95% CI, 2.3-8.3) for other hospitalized hemorrhages, and 4.7 (95% CI, 1.7-12.7) for hematologic malignancy. The 5-year all-cause mortality RR was 2.3 (95% CI, 1.8-3.0). In summary, primary chronic ITP was associated with substantially increased long-term risk of infections, hemorrhagic episodes requiring hospitalization, hematologic malignancies, and mortality.

摘要

慢性原发性免疫性血小板减少症 (ITP) 患者的长期预后数据有限。我们比较了 ITP 患者与普通人群的感染风险、导致住院的出血、血液系统恶性肿瘤以及全因和死因特异性死亡率。我们使用基于人群的医疗数据库,确定了 1996 年至 2007 年间诊断为原发性慢性 ITP 的 407 名患者和 4069 名在年龄、性别和合并症水平上与患者相匹配的普通人群成员。我们使用 Cox 回归分析来估计调整年龄(≤60 岁或>60 岁)、性别、日历年份和合并症水平后的率比(RR)。与普通人群相比,慢性 ITP 患者的 1 年感染 RR 为 4.5(95%置信区间 [CI],3.3-6.1)。调整后的 RR 在随访的第二至第五年下降至 1.8(95%CI,1.3-2.5)。调整后的 5 年 RR 为颅内出血住院 3.2(95%CI,1.2-9.0)、其他出血住院 4.4(95%CI,2.3-8.3)和血液系统恶性肿瘤 4.7(95%CI,1.7-12.7)。5 年全因死亡率 RR 为 2.3(95%CI,1.8-3.0)。总之,原发性慢性 ITP 与感染、需要住院的出血发作、血液系统恶性肿瘤和死亡率的长期风险显著增加相关。

相似文献

1
Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study.原发性慢性免疫性血小板减少症患者的长期临床结局:一项丹麦基于人群的队列研究。
Blood. 2011 Mar 31;117(13):3514-20. doi: 10.1182/blood-2010-10-312819. Epub 2011 Jan 24.
2
Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study.成人原发性免疫性血小板减少症患者的20年死亡率:一项基于丹麦人群的队列研究。
Br J Haematol. 2014 Jul;166(2):260-7. doi: 10.1111/bjh.12869. Epub 2014 Apr 2.
3
Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006-2012.2006 - 2012年美国成年免疫性血小板减少性紫癜住院患者的住院时间、住院费用及院内死亡率
Vasc Health Risk Manag. 2017 Jan 20;13:15-21. doi: 10.2147/VHRM.S123631. eCollection 2017.
4
Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study.原发性免疫性血小板减少症成年患者的心理健康和精神类处方药物使用情况:一项全国范围内基于人群的队列研究。
Haematologica. 2024 Sep 1;109(9):2944-2954. doi: 10.3324/haematol.2024.285364.
5
Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population-based study.成人慢性原发和继发免疫性血小板减少症患者的生存情况:一项基于人群的研究。
Transfusion. 2023 Feb;63(2):415-426. doi: 10.1111/trf.17212. Epub 2023 Jan 5.
6
Comorbidities in patients with persistent or chronic immune thrombocytopenia.持续性或慢性免疫性血小板减少症患者的合并症。
Int J Hematol. 2010 Sep;92(2):289-95. doi: 10.1007/s12185-010-0636-3. Epub 2010 Jul 24.
7
Impact of immune thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction.免疫性血小板减少性紫癜对急性心肌梗死患者临床结局的影响。
Clin Cardiol. 2020 Jan;43(1):50-59. doi: 10.1002/clc.23287. Epub 2019 Nov 11.
8
Geographic disparities in the care and outcomes in adult chronic immune thrombocytopenia.成人慢性免疫性血小板减少症治疗及预后的地域差异
Thromb Res. 2023 May;225:87-94. doi: 10.1016/j.thromres.2023.03.011. Epub 2023 Mar 30.
9
Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.特发性血小板减少性紫癜:阿拉巴马儿童医院的一项为期10年的自然史研究。
Clin Pediatr (Phila). 2004 Oct;43(8):691-702. doi: 10.1177/000992280404300802.
10
Cancer risk in patients with primary immune thrombocytopenia - A Swedish nationwide register study.原发性免疫性血小板减少症患者的癌症风险 - 一项瑞典全国登记研究。
Cancer Epidemiol. 2020 Dec;69:101806. doi: 10.1016/j.canep.2020.101806. Epub 2020 Sep 15.

引用本文的文献

1
Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States.免疫性血小板减少症(ITP)患者调查:确定美国患者在治疗和疾病控制方面未满足的需求。
Br J Haematol. 2025 Sep;207(3):1038-1046. doi: 10.1111/bjh.20257. Epub 2025 Aug 17.
2
Multicenter Single-Blind Randomized Controlled Trial of the Romiplostim Biosimilar.罗米司亭生物类似药的多中心单盲随机对照试验
EJHaem. 2025 Jul 24;6(4):e70105. doi: 10.1002/jha2.70105. eCollection 2025 Aug.
3
Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study.
原发性免疫性血小板减少症成年患者的心理健康和精神类处方药物使用情况:一项全国范围内基于人群的队列研究。
Haematologica. 2024 Sep 1;109(9):2944-2954. doi: 10.3324/haematol.2024.285364.
4
Rilzabrutinib placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study.利扎布替尼对比安慰剂治疗成人和青少年持续性或慢性免疫性血小板减少症:LUNA 3期III期研究
Ther Adv Hematol. 2023 Oct 18;14:20406207231205431. doi: 10.1177/20406207231205431. eCollection 2023.
5
Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia.生物类似药罗米司亭与原研罗米司亭治疗慢性免疫性血小板减少症患者的疗效与安全性比较
Indian J Hematol Blood Transfus. 2023 Jul;39(3):435-441. doi: 10.1007/s12288-022-01602-5. Epub 2022 Nov 15.
6
Older Adults and Immune Thrombocytopenia: Considerations for the Clinician.老年人与免疫性血小板减少症:临床医生的相关考虑。
Clin Interv Aging. 2023 Jan 26;18:115-130. doi: 10.2147/CIA.S369574. eCollection 2023.
7
Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population-based study.成人慢性原发和继发免疫性血小板减少症患者的生存情况:一项基于人群的研究。
Transfusion. 2023 Feb;63(2):415-426. doi: 10.1111/trf.17212. Epub 2023 Jan 5.
8
Occurrence and role of lung megakaryocytes in infection and inflammation.肺巨核细胞在感染和炎症中的发生和作用。
Front Immunol. 2022 Nov 29;13:1029223. doi: 10.3389/fimmu.2022.1029223. eCollection 2022.
9
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.开发和验证 ITP 中 ICH 死亡率预测模型:一项全国代表性多中心研究。
Blood Adv. 2022 Jul 26;6(14):4320-4329. doi: 10.1182/bloodadvances.2022007226.
10
Pre-Procedure Thrombocytopenia and Leukopenia Association with Risk for Infection in Image-Guided Tunneled Central Venous Catheter Placement.术前血小板减少和白细胞减少与影像引导下经皮隧道式中心静脉导管置管感染风险的关系。
Tomography. 2022 Mar 1;8(2):627-634. doi: 10.3390/tomography8020052.